B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
PHASE1
This phase I trial tests safety, side effects and best dose of B-cell activ...
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
PHASE1
This phase I trial studies the side effects and best dose of autologous CD8...
Status
Withdrawn
Location
Fred Hutch/University of Washington Cancer Consortium
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
PHASE1
This phase I trial finds the best dose of PVEK when given together with flu...
Status
Active Not Recruiting
Location
Fred Hutch/University of Washington Cancer Consortium